While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that leverages its financial strength to beat its competitors and two best left off your watchlist.
Two Stocks to Sell:
Gibraltar (ROCK)
Trailing 12-Month Free Cash Flow Margin: 5.7%
Gibraltar (NASDAQ: ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Do We Think ROCK Will Underperform?
- Annual sales declines of 3.1% for the past two years show its products and services struggled to connect with the market during this cycle
- Earnings per share have dipped by 9.1% annually over the past two years, which is concerning because stock prices follow EPS over the long term
- 7× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Gibraltar’s stock price of $37.51 implies a valuation ratio of 0.9x trailing 12-month price-to-sales. If you’re considering ROCK for your portfolio, see our FREE research report to learn more.
AdaptHealth (AHCO)
Trailing 12-Month Free Cash Flow Margin: 5.8%
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
Why Does AHCO Give Us Pause?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
- Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 12.4% annually
- Below-average returns on capital indicate management struggled to find compelling investment opportunities, and its shrinking returns suggest its past profit sources are losing steam
AdaptHealth is trading at $9.74 per share, or 10.3x forward P/E. Dive into our free research report to see why there are better opportunities than AHCO.
One Stock to Buy:
ServiceNow (NOW)
Trailing 12-Month Free Cash Flow Margin: 34.6%
Built on a single code base that processes more than 80 billion workflows and 6.5 trillion transactions annually, ServiceNow (NYSE: NOW) provides a cloud-based platform that helps organizations automate and digitize workflows across departments, from IT and HR to customer service and security.
Why Are We Backing NOW?
- Ability to secure long-term commitments with customers is evident in its 21.8% ARR growth over the last year
- User-friendly software enables clients to ramp up spending quickly, leading to the speedy recovery of customer acquisition costs
- NOW is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
At $114.14 per share, ServiceNow trades at 7.8x forward price-to-sales. Is now the time to initiate a position? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
